Letters & Theses

Jeffrey Smith · Starboard Value

A letter to the shareholders of Bristol-Myers Squibb Company

Starboard's February 2019 letter to Bristol-Myers Squibb shareholders on the Celgene deal

Published 28 Feb 2019Available at SEC.govActivist letter · Investment

The view as filed on 28 Feb 2019, not a statement of what the author thinks today.

Page 1 of the proxy filing, as filed with the SEC

Page 1 of the proxy filing, as filed with the SEC

What to notice

  1. 1

    The patent cliff is the centrepiece: Revlimid, a small molecule drug with about $9.7 billion of 2018 sales and over 60% of Celgene's revenue, faced generic competition from 2022, and Starboard shows small molecule sales falling far faster than biologics after exclusivity ends.

Continue the investment thesis

See the 3 remaining takeaways on what this investor is arguing and why, and every analysis across the Letters & Theses library.

Checking what you can open…

“Bristol-Myers is knowingly acquiring a massive patent cliff”
Jeffrey Smith, 28 Feb 2019

Why read it

A rare activist case against a merger built on product economics, showing how patent expiry, pipeline risk and diligence timing can be weighed against a headline deal.

About this letter

Jeffrey C. Smith, managing member of Starboard Value, signed this letter to the shareholders of Bristol-Myers Squibb on 28 February 2019. Bristol-Myers had announced its intention to acquire Celgene for approximately $91 billion in cash and stock, which Starboard calls one of the largest ever pharmaceutical mergers. Starboard said it would vote all its shares against the proposals at the special meeting scheduled for 12 April 2019, would solicit other shareholders to do the same, and had nominated a slate of directors for the 2019 annual meeting should the deal be voted down.

The letter opens with Bristol-Myers' share price record against its peers and the market, then argues its position under five headings: the product Celgene depends on, the pipeline expected to replace it, the diligence process, the company's presentation of the deal's value, and the alternatives open to an independent Bristol-Myers.

Companies

  • Bristol-Myers Squibb Company BMY
  • Celgene Corporation CELG

Themes

  • capital allocation
  • valuation
  • risk
  • governance
  • strategy

L3VLUP does not host this document. It belongs to Starboard Value and is a public SEC filing; the notes above are L3VLUP’s reading of it.

The same argument, elsewhere

Holdings named in this letter

Starboard Value LP’s reported 13F position in each company the letter names, in the quarter ending on or before the letter and the quarter after. Shown because the letter names the company. A letter is commentary; it is not a record of why a position changed.

  • BMY Bristol-Myers Squibb Company · Subject of the letter

    Before the letter
    31 Dec 2018 (Q4 2018 13F): not among Starboard Value LP’s listed positions. A holding below the listed range, under another security, or none at all would read the same.
    After the letter
    31 Mar 2019 (Q1 2019 13F): not among Starboard Value LP’s listed positions. A holding below the listed range, under another security, or none at all would read the same.
  • CELG Celgene Corporation · Mentioned

    The 13F Explorer has no record for CELG, so no position is stated.

Everything Starboard Value LP reports (13F) · Every letter beside its positions